Fulcrum Therapeutics Inc (FULC)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

26 LANDSDOWNE STREET CAMBRIDGE, MA 02139

Fulcrum Therapeutics, Inc. produces and distributes pharmaceutical products. The Company develops and produces drugs for transforming gene regulation in diseases. Fulcrum Therapeutics serves the healthcare sectors in the State of Massachusetts.

Data as of 2020-08-01
Market Cap434.88 Million Shares Outstanding27.403 Million Avg 30-day Volume79.929 Thousand
P/E Ratio Dividend Yield EPS-0.29
Price/Sales579.84 Price cash flow ratio Price free cash flow ratio-12.8
Book Value2.58 Price to Tangible Book6.11 Alpha0.05
Short Interest Ratio % Short Interest to Float R-squared0.111044
BETA2.02872 52-week High/Low22.96 / 4.37 Stddev0.39422
View SEC Filings from FULC instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 3 0 (0.0%)
13F Filers holding this stock: 46 14 (0.92%)
Aggregate 13F shares on 03/31/2020: 16.1 Million 4.744 Million
Aggregate 13F shares on 12/31/2019: 15.071 Million 4.07 Million
Percent change: 6.83% 16.57%
Funds creating new positions: 11 4
Funds Adding to an existing position: 23 6
Funds closing out their position: 3 2
Funds reducing their position: 5 3
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FULC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FULC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

11 Thousand total shares from 7 transactions

Exercise Derivative Conversion (M)

5 Thousand total shares from 4 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SANOFI

  • 10% Owner
520,125 2020-07-28 0

GLAXOSMITHKLINE PLC

  • 10% Owner
4,626,389 2020-07-24 0

GOULD ROBERT J SEE REMARKS

  • Officer
  • Director
534,845 2020-07-08 10

WALLACE OWEN B. CHIEF SCIENTIFIC OFFICER

  • Officer
127,088 2020-07-08 7

GERAGHTY JAMES A

  • Director
91,253 2020-07-01 1

CASDIN PARTNERS MASTER FUND, L.P.

CASDIN CAPITAL, LLC

CASDIN PARTNERS GP, LLC

CASDIN ELI

  • 10% Owner
5,840,107 2020-07-01 0

CADAVID DIEGO SVP CLINICAL DEVELOPMENT

  • Officer
65,714 2020-07-01 10

COLLINS JAMES J.

  • Director
0 2020-06-11 1

LEVIN MARK J

  • Director
  • 10% Owner
0 2020-06-11 1

HAVILAND KATE

  • Director
0 2020-06-11 1

EZEKOWITZ ALAN

  • Director
0 2020-06-11 1

DORTON KATINA

  • Director
10,600 2020-06-04 2

THOMSON PETER G. VP FINANCE & ACCOUNTING

  • Officer
21,071 2020-05-11 3

THIRD ROCK VENTURES IV, L.P.

THIRD ROCK VENTURES GP IV, L.P.

TRV GP IV, LLC

  • 10% Owner
1,419,900 2020-02-18 0

STUART BRYAN CHIEF OPERATING OFFICER

  • Officer
0 2020-01-23 1

THIRD ROCK VENTURES III, L.P.

THIRD ROCK VENTURES GP III, L.P.

TRV GP III, LLC

STARR KEVIN P

TEPPER ROBERT I

  • 10% Owner
5,962,202 2019-07-22 0

6 DIMENSIONS CAPITAL, L.P.

  • 10% Owner
559,821 2019-07-22 0

SECTION 32 FUND 2, LP

SECTION 32 GP 2, LLC

MARIS WILLIAM J

  • 10% Owner
464,285 2019-07-22 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

WALLACE OWEN B. - Officer CHIEF SCIENTIFIC OFFICER

2020-07-08 S 2,951 $20.00 d 127,088 127,088.00 direct yes

GOULD ROBERT J - Director - Officer SEE REMARKS

2020-07-08 S 2,500 $20.00 d 534,845 534,845.00 direct yes

WALLACE OWEN B. - Officer CHIEF SCIENTIFIC OFFICER

2020-07-08 M 2,951 $7.84 a 130,039 127,088.00 direct yes

WALLACE OWEN B. - Officer CHIEF SCIENTIFIC OFFICER

2020-07-08 M 2,951 d 81,942 127,088.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-07-01 S 1,071 $18.30 d 65,714 65,714.00 direct yes

WALLACE OWEN B. - Officer CHIEF SCIENTIFIC OFFICER

2020-06-30 M 141 d 84,893 127,088.00 direct yes

WALLACE OWEN B. - Officer CHIEF SCIENTIFIC OFFICER

2020-06-30 S 141 $20.00 d 127,088 127,088.00 direct yes

WALLACE OWEN B. - Officer CHIEF SCIENTIFIC OFFICER

2020-06-30 M 141 $7.84 a 127,229 127,088.00 direct yes

GOULD ROBERT J - Director - Officer SEE REMARKS

2020-06-25 S 2,500 $20.80 d 537,345 537,345.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-06-25 M 1,459 $4.83 a 68,244 66,785.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-06-25 M 1,459 d 12,277 66,785.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-06-25 S 1,459 $22.00 d 66,785 66,785.00 direct yes

GERAGHTY JAMES A - Director

2020-06-11 A 9,285 a 9,285 0.00 direct

EZEKOWITZ ALAN - Director

2020-06-11 A 9,285 a 9,285 0.00 direct

LEVIN MARK J - Director - > 10% Owner

2020-06-11 A 9,285 a 9,285 0.00 direct

HAVILAND KATE - Director

2020-06-11 A 9,285 a 9,285 0.00 direct

COLLINS JAMES J. - Director

2020-06-11 A 9,285 a 9,285 0.00 direct

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-06-10 M 401 $4.83 a 67,186 66,785.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-06-10 M 401 d 13,736 66,785.00 direct yes

CADAVID DIEGO - Officer SVP CLINICAL DEVELOPMENT

2020-06-10 S 401 $22.00 d 66,785 66,785.00 direct yes
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments